Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Harris

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic CancerLi Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck CancerMitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, et al.
JAMA Oncology|September 28, 2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical TrialStuart J Wong, Pedro A Torres-Saavedra, Nabil F Saba, et al.
Nature|December 14, 2012
Bright radio emission from an ultraluminous stellar-mass microquasar in M 31Matthew J Middleton, James C A Miller-Jones, Sera Markoff, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 30, 2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC GroupBenjamin Lacas, Alexandra Carmel, Cécile Landais, et al.
Nature|February 16, 2017
Whole-genome landscape of pancreatic neuroendocrine tumoursAldo Scarpa, David K Chang, Katia Nones, et al.
Nature|September 28, 2017
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumoursAldo Scarpa, David K Chang, Katia Nones, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic CancerLi Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck CancerMitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, et al.
JAMA Oncology|September 28, 2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical TrialStuart J Wong, Pedro A Torres-Saavedra, Nabil F Saba, et al.
Nature|December 14, 2012
Bright radio emission from an ultraluminous stellar-mass microquasar in M 31Matthew J Middleton, James C A Miller-Jones, Sera Markoff, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 30, 2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC GroupBenjamin Lacas, Alexandra Carmel, Cécile Landais, et al.
Nature|February 16, 2017
Whole-genome landscape of pancreatic neuroendocrine tumoursAldo Scarpa, David K Chang, Katia Nones, et al.
Nature|September 28, 2017
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumoursAldo Scarpa, David K Chang, Katia Nones, et al.
Pageof 13